The Bureau of Cannabis Control is slated to start
issuing and processing applications on January 1, 2018. Further regulations will be presented
in November of this year, and the California Department of Consumer Affairs just
seated the long-waited Cannabis Advisory Committee mandated by the state’s new
cannabis rules.
What is absent on this committee is any authentic
patient voice or social justice advocates. However, this has been the case in Sacramento during all
medical cannabis policy discussions.
Patient advocates have had to demand to be heard or be ignored. Now that the potential revenue from
adult recreational cannabis sales and production is being projected, affordable
access to medical cannabis for disabled and low-income patients is the furthest
thing on the minds of the new Cannabis Bureaucracy.
Hopefully, the California Cannabis Bureaucracy
realizes that we could find ourselves back in a federally hostile environment. Who did they seat to tackle the
possibility that our U.S. Attorney General and Department of Justice may decide
to enforce the Controlled Substances Act, again? Who will deal with the fallout and stand up for the
political prisoners?
What is present on this committee is the Drug
Policy Alliance. Members of the
Drug Policy Alliance are gaining seats on committees and commissions around the
state. Since DPA’s political
action committee donated a significant amount of money to Prop. 64, this would seem
to be a conflict. However, this
works out wonderfully for George Soros, who founded and funds DPA, and is heavily
vested in Monsanto. Monsanto stands to win the most from
Prop. 64, by acquiring the largest permits and controlling the seeds for
recreational, medical and hemp stains.
With Soros’ employees serving around the state the mega-corporate take
over of California’s cannabis industry is moving right along.
Despite how the advisory or oversight bodies may
be stacked, the regulations themselves equate impractical policy. Many current businesses will find it
burdensome and too expensive to comply.
This creates a monopoly for wealthy, elite players to saturate the
marketplace. True patients and their
providers will be priced out and in jeopardy. Some operations will go deep underground, adding to existing
environmental concerns about unregulated cultivation.
Patients are urged to contact:
Department of Consumer Affairs – Bureau of Cannabis
Control
Attn: Lori Ajax, Chief, Bureau of Cannabis
Control;
Dean R. Grafilo, Director, California Department
of Consumer Affairs;
And Members of the Cannabis Advisory Committee
Or (800) 952-5210
Let them know that you are patient that relies on
consistent and affordable access to medical cannabis, and you are concerned
that over-regulation, permitting fees and taxes for medical cannabis are going
to put your collective out of business or make it so you can no longer afford
your medicine.
Send your comments and concerns to your California
state representatives as well:
Find Your California Representative
*****
Some related links:
Department of Consumer Affairs Announces
Appointments to Cannabis Advisory Committee
L.A. City Council approves new Cannabis Department
head
George Soros And Big Agriculture Move The
Marijuana Movement
How Monsanto & Bayer Are Trying To Take Over
The Cannabis Industry
The Corporate Billionaires’ Hostile Attempt To
Take Over The California Cannabis Industry in 2016
Legalization, 4 Years Later: What Happened In
Washington State?
#####
